AnalystsDaniel StauderDaniel Stauder's Stock Forecasts
AnalystsDaniel Stauder
Analyst Ranking
Top 26%
#1334 out of 5177 analysts
Average Return
+15.88%
Win Rate
70%14 out of 20
Risk vs Reward
Poor
Good
Daniel Stauder's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Lemaitre Vascular IncLMAT | +80.09% | $48.46 | $87.27 | 2023-10-22 - 2024-10-22 | Buy |
Artivion IncAORT | +69.76% | $25.56 | $43.39 | 2025-02-24 - 2026-01-16 | Buy |
Artivion IncAORT | +61.84% | $26.86 | $43.47 | 2024-10-22 - 2025-10-22 | Buy |
Artivion IncAORT | +58.24% | $27.42 | $43.39 | 2025-05-05 - 2026-01-16 | Buy |
Artivion IncAORT | +44.99% | $29.83 | $43.25 | 2024-12-09 - 2025-12-09 | Buy |
Daniel Stauder Analyst Color
Get additional color on Daniel Stauder's coverage of popular stocks
Daniel Stauder's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Stereotaxis IncSTXS | 1 | Buy | $4.00 | +49.25% | Initiates Coverage On | a month ago |
Artivion IncAORT | 7 | Buy | $53.00 | +22.15% | Maintains | 2 months ago |
Atricure IncATRC | 6 | Buy | $60.00 | +53.61% | Reiterates | 9 months ago |
Neuronetics IncSTIM | 1 | Buy | $7.00 | +268.42% | Maintains | 10 months ago |
Lemaitre Vascular IncLMAT | 4 | Strong Buy | $110.00 | +24.62% | Maintains | a year ago |
Axon Enterprise IncAXON | 1 | Buy | $725.00 | +13.99% | Reiterates | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.